These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 34905009

  • 21. The Effects of N-Acetyl-L-Leucine on the Improvement of Symptoms in a Patient with Multiple Sulfatase Deficiency.
    Saberi-Karimian M, Houra M, Jamialahmadi T, Sarvghadi P, Nikbaf M, Akhlaghi S, Sahebkar A.
    Cerebellum; 2023 Dec; 22(6):1250-1256. PubMed ID: 36482027
    [Abstract] [Full Text] [Related]

  • 22. Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms: A Randomized Clinical Trial.
    Che X, Wang J, Sun W, He J, Wang Q, Zhu D, Zhu W, Zhang J, Dong J, Xu J, Zheng F, Zhou J, Zhao W, Lin Q, Ye L, Zhao X, Xu Z, Chen Y, Wang J, Wu W, Zhai L, Zhou Y, Zheng J, Zhang X.
    JAMA Netw Open; 2023 Jun 01; 6(6):e2317860. PubMed ID: 37307001
    [Abstract] [Full Text] [Related]

  • 23. Comparing Cerebellar tDCS and Cerebellar tACS in Neurodegenerative Ataxias Using Wearable Sensors: A Randomized, Double-Blind, Sham-Controlled, Triple-Crossover Trial.
    Libri I, Cantoni V, Benussi A, Rivolta J, Ferrari C, Fancellu R, Synofzik M, Alberici A, Padovani A, Borroni B.
    Cerebellum; 2024 Apr 01; 23(2):570-578. PubMed ID: 37349632
    [Abstract] [Full Text] [Related]

  • 24. Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.
    Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, Feil K.
    Cerebellum Ataxias; 2016 Apr 01; 3():8. PubMed ID: 27073690
    [Abstract] [Full Text] [Related]

  • 25. Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy.
    Gazulla J, Benavente I.
    Acta Neurol Scand; 2007 Oct 01; 116(4):235-8. PubMed ID: 17824901
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.
    Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA.
    J Neurol; 2022 Mar 01; 269(3):1651-1662. PubMed ID: 34387740
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.
    Lancet; 2017 Mar 25; 389(10075):1206-1217. PubMed ID: 28215362
    [Abstract] [Full Text] [Related]

  • 28. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
    Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, Frontali M, Ferraldeschi M, Vulpiani MC, Ponzelli F, Salvetti M, Orzi F, Petrucci A, Vanacore N, Casali C, Ristori G.
    Lancet Neurol; 2015 Oct 25; 14(10):985-91. PubMed ID: 26321318
    [Abstract] [Full Text] [Related]

  • 29. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M, HELP Investigators.
    JAMA; 2018 Nov 27; 320(20):2108-2121. PubMed ID: 30480729
    [Abstract] [Full Text] [Related]

  • 30. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R, Teufel J, Feil K, Muth C, Strupp M.
    J Neurol; 2016 Apr 27; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [Abstract] [Full Text] [Related]

  • 31. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A.
    Lancet Neurol; 2018 Sep 27; 17(9):749-759. PubMed ID: 30055903
    [Abstract] [Full Text] [Related]

  • 32. Acetyl-DL-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?
    Becker-Bense S, Kaiser L, Becker R, Feil K, Muth C, Albert NL, Unterrainer M, Bartenstein P, Strupp M, Dieterich M.
    J Neurol; 2023 Jan 27; 270(1):44-56. PubMed ID: 35876876
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
    Martakis K, Claassen J, Gascon-Bayari J, Goldschagg N, Hahn A, Hassan A, Hennig A, Jones S, Kay R, Lau H, Perlman S, Sharma R, Schneider S, Bremova-Ertl T.
    Neurology; 2023 Mar 07; 100(10):e1072-e1083. PubMed ID: 36456200
    [Abstract] [Full Text] [Related]

  • 34. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
    Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J, COMBINE Study Group.
    Lancet Psychiatry; 2022 Apr 07; 9(4):291-306. PubMed ID: 35276079
    [Abstract] [Full Text] [Related]

  • 35. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.
    Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL.
    Neurology; 2012 Feb 21; 78(8):545-50. PubMed ID: 22323747
    [Abstract] [Full Text] [Related]

  • 36. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS.
    Epilepsy Curr; 2019 Feb 21; 19(2):93-95. PubMed ID: 30955420
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E.
    JAMA Dermatol; 2019 Dec 01; 155(12):1371-1379. PubMed ID: 31577341
    [Abstract] [Full Text] [Related]

  • 38. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.
    Lancet Respir Med; 2020 Feb 01; 8(2):147-157. PubMed ID: 31578169
    [Abstract] [Full Text] [Related]

  • 39. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P, Xie J, Adeleine P, Michel D, Vighetto A, Honnorat J, Dumas R, Nighoghossian N, Laurent B.
    Arch Neurol; 1997 Jun 01; 54(6):749-52. PubMed ID: 9193210
    [Abstract] [Full Text] [Related]

  • 40. Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases.
    Wessel K, Langenberger K, Nitschke MF, Kömpf D.
    Arch Neurol; 1997 Apr 01; 54(4):397-400. PubMed ID: 9109740
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.